
SHPG
Other · Other · $163.90B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2018
EPS trend, 90 days to now · -100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 1, 2018 | Time not confirmed | 3.58 | 3.64 | +1.7% |
| Jul 31, 2018 | Time not confirmed | 3.67 | 3.88 | +5.7% |
| Apr 26, 2018 | Time not confirmed | 3.55 | 3.86 | +8.7% |
| Feb 14, 2018 | Time not confirmed | 3.88 | 3.99 | +2.8% |
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR…